ResearchMoz

LY2189265 (Type 2 Diabetes) Analysis and Forecasts to 2020

GlobalData
Published Date » 2012-01-31
No. Of Pages » 42

GlobalDatas pharmaceuticals report, LY2189265 (Type 2 Diabetes) Analysis and Forecasts to 2020 provides LY2189265 sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of LY2189265 including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of LY2189265 including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for LY2189265 in each of the seven major markets
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19
6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24

7 LY2189265 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Clinical Studies 25
7.3.1 Phase II 25
7.3.2 Phase III 25
7.4 Factors Affecting Sales of LY2189265 26
7.4.1 Once Weekly Dosage 26
7.4.2 Competition from Januvia 26
7.4.3 Approval of Bydureon 26
7.5 Drug Evaluation 26
7.5.1 Drug Risk Benefit Score 26
7.5.2 Intensity of Competition 27
7.6 Sales Forecasts 27
7.6.1 Target Patient Pool for LY2189265 27
7.6.2 Dosing 27
7.6.3 Market Penetration 28
7.6.4 Annual Cost of Therapy 29
7.6.5 Sales Projections of LY2189265 30

8 Diabetes Market: Appendix 39
8.1 Market Definitions 39
8.2 List of Abberiviations 39
8.3 Research Methodology 39
8.3.1 Coverage 39
8.3.2 Secondary Research 40
8.3.3 Forecasting 40
8.3.4 Number of patients approved to take the drug 40
8.3.5 Net Penetration of Drug 41
8.3.6 Net Annual Dosing 41
8.3.7 Annual Cost of Therapy 41
8.4 Drug Sales Estimates Model 41
8.5 Contact Us 41
8.6 Disclaimer 41
8.7 Sources 42

List of Tables


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs by Sales ($m), 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trials 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 9: Drug Risk Benefit Score of LY2189265 26
Table 10: Estimated Annual Cost of Therapy of LY189265, 2014 29
Table 11: LY2189265, Type 2 Diabetes, Global, Sales Forecasts ($m), 20142020 30
Table 12: LY2189265, Type 2 Diabetes, The US, Sales Forecasts ($m), 20142020 31
Table 13: LY2189265, Type 2 Diabetes, The UK, Sales Forecasts ($m), 20142020 32
Table 14: LY2189265, Type 2 Diabetes, France, Sales Forecasts ($m), 20142020 33
Table 15: LY2189265, Type 2 Diabetes, Germany, Sales Forecasts ($m), 20142020 34
Table 16: LY2189265, Type 2 Diabetes, Italy, Sales Forecasts ($m), 20142020 35
Table 17: LY2189265, Type 2 Diabetes, Spain, Sales Forecasts ($m), 20142020 36
Table 18: LY2189265, Type 2 Diabetes, Japan, Sales Forecasts ($m), 20162020 37

List of Figures


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylureas 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Branded Market Share by Value, By Class (%), 2010 24
Figure 12: LY2189265, Type 2 Diabetes, Global, Sales Forecasts ($m), 20142020 30
Figure 13: LY2189265, Type 2 Diabetes, The US, Sales Forecasts ($m), 20142020 31
Figure 14: LY2189265, Type 2 Diabetes, The UK, Sales Forecasts ($m), 20142020 32
Figure 15: LY2189265, Type 2 Diabetes, France, Sales Forecasts ($m), 20142020 33
Figure 16: LY2189265, Type 2 Diabetes, Germany, Sales Forecasts ($m), 20142020 34
Figure 17: LY2189265, Type 2 Diabetes, Italy, Sales Forecasts ($m), 20122020 35
Figure 18: LY2189265, Type 2 Diabetes, Spain, Sales Forecasts ($m), 20142020 36
Figure 19: LY2189265, Type 2 Diabetes, Japan, Sales Forecasts ($m), 20162020 37
Figure 20: LY2189265, Type 2 Diabetes, Global, Sales Distribution (%), 2020 38
Figure 21: Patients Approved for the Drug 40

Upcoming Reports:

Medical Robotics Market - Global Industry Analysis, Size, Growth, Share And Forecast, 2012 - 2018
By - Transparency Market Research
Robotics is an integral part of modern medicine and it is a recent phenomenon as compared to developments that have taken place in other industries. Medical robotics is helpful in training future medical professionals and providing comfort and care to elderly patients. The other benefits of medical robotics are the high precision, reduced hospital stay and smaller incisions. Moreover, it gives a real-life experience to future doctors since this technology involves robots mimicking a patient’s feelings. Although it is gaining popularity in the medical sector, the initial set-up...
Hydrogen Generator Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth And Forecast 2014 - 2020
By - Transparency Market Research
Escalating demand for energy and rising cost of fossil fuels is likely to propel the demand for hydrogen generator. Rise in application of hydrogen generator is anticipated to drive growth in the global hydrogen generator market. Method of hydrogen generation includes: steam forming of methane and natural gas. Low prices of natural gas and ease of availability are expected to drive growth in the global hydrogen generator market. The global market for hydrogen generator can be segmented on the basis of product type and geography. On the basis of product type, the global market for...
Bamboo Composites For Wind Power Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Bamboo composites are made from the natural fibers of bamboos. Bamboo composites are biodegradable, hence has advantage over the plastic composites as a green product. Use of bamboo composites in the wind turbines offers advantages over the plastic composites such as lost cost, light weight, biodegradable and reusable.   The global bamboo composites market for wind power is mainly driven by use of green energy and government policies for use of renewable energy sources. Government policies across several nations are enforcing the use of wind energy for electricity generation...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

Ford Recalls 65,000 Fusion Models Due to Issues in Ignition Key
Nov 20, 2014  
If anything defines the world of automobiles currently, it would be recalls. It seems that a flood of automobiles has surrounded the global automobiles industry, which once represented a flourishing and highly profitable industry.  The current automobile giants ordering yet another recall is Ford Motors Co. Ford declared on Tuesday that it is recalling nearly 65,000 sedans from...
3D Printed Heart Model for Better Cardiological Treatment
Nov 20, 2014  
According to research carried out by the American Heart Association’s Scientific Sessions 2014, surgeons will be able to treat complex heart disorders in patients, with the help of a three dimensional experimental printed model of the heart. For surgical planning, most cardiac surgeons make use of two dimensional images of the heart taken by MRI, ultrasound, and X-ray. But the problem is...
Los Angeles Auto Show Kicks Off
Nov 20, 2014  
The Los Angeles Auto Show kicked off on Wednesday with a rather upbeat mood. Motoring machines, industry metrics, and hybrid models – the show has lived up to its reputation once more. The Los Angeles Auto Show has begun touring North America from the Los Angeles Convention Center, and the commencement has already had an impact on the market. Gasoline prices dropped under US$3...
Scottish Government to Inject 200 Million Pounds in the Housing Sector
Nov 19, 2014  
The construction and the housing industries of Scotland will get a major financial boost from the Scottish government in terms of additional funding worth 200 million pounds. The main rationale of such a financial boost is to stimulate the housing sector and also safeguarding employment in the construction industry. The housing minister of Scotland has requested the housing leaders to work...
Quarterly Dividend of $0.10 Declared by Tyson Foods, Inc.
Nov 19, 2014  
A quarterly dividend on November 18th was declared by Tyson Foods, reported Analyst Ratings Network.com. The shareholders of the February 27th record will be awarded a dividend of 0.10 per share on March 13th.  This represents a yield of 0.94% and a $0.40 dividend on an annualized basis. However, the ex-dividend date of this particular dividend is February 25th.  Such...